Insider buying last 90 days
No open-market insider purchases were filed for ALKS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Alkermes reported third-quarter 2026 results this week, with proprietary product sales up 31% year-over-year and earnings surpassing estimates at $0.52 per share against a $0.52 actual versus a -$0.04 estimate, compared with $0.49 per share a year ago. Management highlighted continued investment in its orexin development portfolio spanning sleep, neuropsychiatric and neurological disorders, alongside research presented at the Neuroscience Education Institute Fall Congress covering its psychiatry and sleep portfolios.
Shares closed at $46.17, up 0.6% on the day, sitting above both the 50-day average of $43.68 and the 200-day average of $40.86, with the 50-day above the 200-day. The GekkoIndex reads 50.4, placing the stock in the Neutral zone, down from a five-day change of -2.2. Price sits within 0.9% of Gekko Fair Value at $46.57, essentially in line with that level.
The next earnings date falls on 24 February 2027, 101 days away and outside a typical 20-trading-day holding window. Over the last 90 days, Congressional activity shows 1 buy and 0 sells. Seasonality from this point in the calendar has averaged -3.2% over the next 20 trading days across 5 years, rising in 3 of those years. Analyst coverage from 13 firms includes 9 buy ratings, 3 hold and 1 sell, with a consensus target of $56.21.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Alkermes scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Above 50 and 200-day
Close $47.03 is above the 50-day ($43.67) and 200-day ($41.13) averages, and the 50-day is above the 200-day.
See the chart49.8, Neutral
Reading 49.8 is in the Neutral zone.
See the GekkoIndex6.0% above
Price is 6% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings+4.5% on average
From this point in the calendar, the next 20 trading days averaged +4.5% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Alkermes closed at $47.03 on Nov 13, 2026, +49.7% over the past year, inside a 52-week range of $27.00 to $55.67.
Use the left and right arrow keys to read daily values.
Put ALKS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Alkermes develops and sells pharmaceutical products aimed at treating conditions such as opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder. It is known for a set of marketed treatments including ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol and opioid dependence, LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for cataplexy or excessive daytime sleepiness in pediatric patients. Alongside these, the company continues work on clinical and preclinical candidates targeting neurological disorders.
Beyond its own product line, Alkermes licenses proprietary technology platforms to other firms, allowing them to develop, manufacture, and bring products to market. It also maintains collaboration agreements with several Janssen Pharmaceutica entities. Its work spans patients and partners in the United States, Ireland, and other international markets.
The company was founded in 1987 and is based in Dublin, Ireland. Its shares are listed on the NASDAQ under the ticker ALKS.
Alkermes’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.8, in the Neutral zone, down 1.9 points over five sessions.
Down 1.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +0.2% | +10.8% | ||
| Accumulation | 232 | +0.6% | +2.2% | ||
| Neutral (current zone) | 368 | +0.4% | +0.3% | ||
| Distribution | 51 | +0.6% | +4.1% | ||
| Selling | 2 | Too few readings yet | |||
Average ALKS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Alkermes trades 6.0% above Gekko Fair Value of $44.35, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Alkermes shares are worth, recalculated every trading day.
$44.35
Gekko Fair Value, Nov 14, 2026
6.0% Overvalued
At the end of Aug 2026 the price was 2.8% below the estimate.
No open-market insider purchases were filed for Alkermes, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ALKS in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 29 |
From congressional disclosures, which report amounts as ranges.
Alkermes has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold ALKS.
Alkermes reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 24, 2027
Expected before the open, 101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $0.52 est −$0.04 | $496.0M est $457.4M | −8.3% |
| May 5, 2026 | $0.38 est −$0.04 | $392.9M est $363.1M | +3.4% |
| Feb 25, 2026 | $0.34 est $0.43 | $384.5M est $378.9M | −8.0% |
| Oct 28, 2025 | $0.65 est $0.39 | $394.2M est $356.9M | +5.8% |
| Jul 29, 2025 | $0.52 est $0.41 | $390.7M est $354.5M | +6.8% |
| May 1, 2025 | $0.13 est $0.25 | $306.5M est $302.9M | +10.5% |
| Feb 12, 2025 | $1.05 est $0.76 | $430.0M est $379.4M | +12.6% |
| Oct 24, 2024 | $0.73 est $0.71 | $378.1M est $381.4M | −6.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Alkermes is $57.74, +22.8% from the last close, from 13 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 13 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | H.C. Wainwright | $50 | +6.3% |
| Nov 4 | Bank of America Securities | — | — |
| Nov 3 | H.C. Wainwright | $43 | −8.6% |
| Nov 3 | RBC Capital | $57 | +21.2% |
| Nov 3 | Wells Fargo | $68 | +44.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Alkermes averaged +4.5% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.2% | 1 of 5 |
| Next 10 trading days | −0.4% | 2 of 5 |
| Next 15 trading days | +4.7% | 4 of 5 |
| Next 20 trading days | +4.5% | 3 of 5 |
| Next 30 trading days | +5.2% | 4 of 5 |
For scale, ALKS’s typical 20-trading-day move in either direction is about 6.7%.
Alkermes’s market cap is $7.90B and revenue of $1.75B over the last twelve months.
Alkermes’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Alkermes’s market cap is $7.90B at the Nov 13, 2026 close of $47.03, with 168.0M shares outstanding.
The consensus analyst 12-month price target for Alkermes is $57.74, +22.8% from the last close. Of the 13 firms that rated the stock in the last 90 days, 9 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Alkermes is overvalued: the Nov 13, 2026 close of $47.03 is 6.0% above Gekko Fair Value of $44.35. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Alkermes is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of −$0.24 per share on revenue of $461.6M. Alkermes beat the earnings estimate in 6 of its last 8 reports, moving 7.7% on average across the report.
Alkermes’s 52-week high is $55.67 and its 52-week low is $27.00; it closed at $47.03 on Nov 13, 2026, +49.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.